Phase 2
N=8
Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral Muscular Dystrophy · Limb Girdle Muscular Dystrophy
Bottom Line
View on ClinicalTrials.gov: NCT02836418 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 7; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- ATYR1940 (Drug)
- Age
- Pediatric, Adult · 16+ yrs
- Sex
- All
- Sponsor
- aTyr Pharma, Inc.
- Primary completion
- Apr 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) |
7; 0 | — |
| PRIMARY Number of Participants With Positive Anti-Drug Antibodies (ADA) |
3 | — |
| PRIMARY Number of Participants With a Jo-1 Antibody (Ab) Test Result ≥1.5 Units/Milliliter (U/mL) |
2 | — |
| PRIMARY Number of Participants With a Clinical Laboratory Abnormality Leading to an AE |
1 | — |
| PRIMARY Number of Participants With a Clinically Significant Pulmonary Function Event Resulting in a TEAE |
— | — |
| PRIMARY Number of Participants With a Clinically Significant Electrocardiogram (ECG) Abnormality Leading to a TEAE |
2 | — |
| PRIMARY Number of Participants With Vital Sign Abnormality Resulting in a TEAE |
— | — |
| PRIMARY Change From Baseline in Manual Muscle Testing (MMT) Score at Week 12 |
229.1; 4.3 | — |
| SECONDARY Change From Baseline in Creatinine Kinase at Week 12 |
-82.3 | — |
Summary
ATYR1940-C-006 is a multi-national, multicenter study being conducted at centers in the United States (US) and Europe who participated in Study ATYR1940-C-003 (Stage 1 only) or Study ATYR1940-C-004 (that is, the parent studies).
Eligibility Criteria
Inclusion Criteria
- Enrolled in and completed the treatment period in the parent study.
- Demonstrated, in the Sponsor's and Investigator's opinions, acceptable tolerability of ATYR1940.
- In the Investigator's opinion, participant has shown acceptable compliance with ATYR1940 and the study procedures in the parent study and is willing and able to comply with all procedures in the current study.
- Is, in the opinion of the Investigator and Sponsor, a suitable candidate for continued ATYR1940 treatment.
- Provide written informed consent or assent after the nature of the study has been explained and prior to the performance of any research-related procedures.
Exclusion Criteria
- Is expected to require treatment with curcumin or systemic albuterol (intermittent inhaled albuterol is permissible) during study participation; or use of a product that putatively enhances muscle growth (for example, insulin-like growth factor, growth hormone) or activity (for example, Coenzyme Q, Coenzyme A, creatine, L-carnitine) on a chronic basis; or statin treatment initiation or significant adjustment to statin regimen (stable, chronic statin use is permissible).
- Planned to receive any vaccination during study participation.
- Abnormal baseline findings, medical condition(s), or laboratory findings that, in the Investigator's opinion, might jeopardize the participant's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
- Evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, dermatological, or gastrointestinal disease, or has a condition that requires immediate surgical intervention, other treatment, or may not allow safe participation.
- If female and of childbearing potential (premenopausal and not surgically sterile), has a positive pregnancy test at entry or is unwilling to use contraception from the time of entry through the 3-month Follow-up visit. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra-uterine device.
- If male, is unwilling to use a condom plus spermicide during sexual intercourse from the time of entry through the 1 month Follow-up visit.
Data sourced from ClinicalTrials.gov (NCT02836418). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.